A compound according to formula (Ia): ** Formula ** or a stereoisomer, a tautomer, a pharmaceutically acceptable salt thereof, in which B is independently selected from -CR3R4O-, -OCR3R4-； L is independently selected from - (CR6R7) q-, NR5 (CR6R7) q- and -O (CR6R7) q-； R1 and R2 are independently selected from H, F, Cl, Br, CN, NRaRa, -C1-4 alkyl substituted with 0-3 Re, C1-4 alkyl substituted with 0-3 Re and - (CH2) rORb； R3 and R4 are independently selected from H and C1-4 alkyl； R5 is independently selected from H and C1-4 alkyl； R6 and R7 are independently selected from H, C1-4 alkyl substituted with 0-4 Re, - (CH2) rORb, - (CH2) rS (O) pRc, - (CH2) rC (>； = O) Rb, - ( CH2) rNRaRa, - (CH2) rC (>； = O) (CH2) rNRaRa, - (CH2) rNRaC (>； = O) Rb, - (CH2) rNRaC (>； = O) ORb, - (CH2) rOC (>； = O) NRaRa, - (CH2) rNRaC (>； = O) NRaRa, - (CH2) rC (>； = O) ORb, - (CH2) rS (O) pNRaRa, - (CH2) rNRaS (O) pN- RaRa , - (CH2) rNRaS (O) pRc, (CH2) C3-6 r-carbocyclyl substituted with 0-3 Re and - (CH2) r-heterocyclyl substituted with 0-3 Re； R8 is selected from aryl, bicyclic carbocyclyl and heteroaryl, each substituted with 0-5 R9； R9 is independently selected from F, Cl, Br, C1-4 alkyl substituted with 0-5 Re, C2-4 alkenyl substituted with 0-5 Re, C2-4 alkynyl substituted with 0-5 Re, nitro, - (CHRd) rS (O) pRc, - (CHRd) rS (O) pNRaRa, - (CHRd) rNRaS (O) Rc, - (CHRd) rORb, - (CH Rd) rCN, - (CHRd) rNRaRa, - (CHRd) rNRaC (>； = O) Rb, - (CHRd) rNRaC (>； = O) NRaRa, - (CHRd) rC (>； = O) ORb, - (CHRd) rC (>； = O) Rb, - (CHRd) rOC (>； = O) Rb, - (CHRd) C (>； = O) NRaRa, - (CHRd) r-cycloalkyl, - (CHRd) r-heterocyclyl, - (CHRd) raryl and (CHRd) r-heteroaryl, wherein said alkyl , cycloalkyl, heterocyclyl, aryl or heteroaryl are substituted with 0-4 Re； alternatively, two adjacent R9 groups combine to form a carbocyclic or heterocyclic ring comprising carbon atoms and 1-3 heteroatoms selected from N, O and S (O) p, wherein the carbocyclic and heterocyclic rings a
